Abstract
The incidence of infections increases during treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) for chronic hepatitis C (CHC). Despite a reduction in neutrophil count, there is no clear relationship between infection occurrence and neutropenia. In the present study we investigated whether HCV treatment alters leukocyte function. We studied cell chemotaxis, reactive oxygen species, neutrophil phagocytosis, CR3 expression, and plasma colony stimulating factors (CSF) in 20 healthy subjects and 20 patients with CHC (10 with cirrhosis) at baseline, during antiviral treatment (at 4, 12, 24 weeks), and 12 weeks after discontinuation. Our results demonstrate that neutrophil chemotaxis and oxidative burst significantly increased during treatment and returned to baseline at the end of therapy. CR3 neutrophil expression was enhanced in baseline CHC compared to controls but did not change during antiviral treatment. Chemotaxis, oxidative burst, phagocytosis, and CSF levels did not differ significantly between patients before treatment and control subjects or among CHC cases according to the presence of cirrhosis in either cell subpopulation. In conclusion, the innate immune cell activity is enhanced in patients with CHC during antiviral treatment and returns to normal after its discontinuation thus possibly playing a role in their susceptibility to infections.
| Original language | English (US) |
|---|---|
| Title of host publication | Annals of the New York Academy of Sciences |
| Pages | 847-857 |
| Number of pages | 11 |
| Volume | 1173 |
| DOIs | |
| State | Published - Sep 2009 |
Publication series
| Name | Annals of the New York Academy of Sciences |
|---|---|
| Volume | 1173 |
| ISSN (Print) | 00778923 |
| ISSN (Electronic) | 17496632 |
Fingerprint
Keywords
- Leukocyte function
- Opportunistic infection
- Pegylated interferon
- Ribavirin
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. / Giorgini, Alessia; Capsoni, Franco; Podda, Mauro; Lleó, Ana; Battezzati, Pier Maria; Ongari, Anna Maria; Selmi, Carlo; Benetti, Alberto; Malinverno, Federica; Rossaro, Lorenzo; Gershwin, M. Eric; Zuin, Massimo.
Annals of the New York Academy of Sciences. Vol. 1173 2009. p. 847-857 (Annals of the New York Academy of Sciences; Vol. 1173).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis
AU - Giorgini, Alessia
AU - Capsoni, Franco
AU - Podda, Mauro
AU - Lleó, Ana
AU - Battezzati, Pier Maria
AU - Ongari, Anna Maria
AU - Selmi, Carlo
AU - Benetti, Alberto
AU - Malinverno, Federica
AU - Rossaro, Lorenzo
AU - Gershwin, M. Eric
AU - Zuin, Massimo
PY - 2009/9
Y1 - 2009/9
N2 - The incidence of infections increases during treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) for chronic hepatitis C (CHC). Despite a reduction in neutrophil count, there is no clear relationship between infection occurrence and neutropenia. In the present study we investigated whether HCV treatment alters leukocyte function. We studied cell chemotaxis, reactive oxygen species, neutrophil phagocytosis, CR3 expression, and plasma colony stimulating factors (CSF) in 20 healthy subjects and 20 patients with CHC (10 with cirrhosis) at baseline, during antiviral treatment (at 4, 12, 24 weeks), and 12 weeks after discontinuation. Our results demonstrate that neutrophil chemotaxis and oxidative burst significantly increased during treatment and returned to baseline at the end of therapy. CR3 neutrophil expression was enhanced in baseline CHC compared to controls but did not change during antiviral treatment. Chemotaxis, oxidative burst, phagocytosis, and CSF levels did not differ significantly between patients before treatment and control subjects or among CHC cases according to the presence of cirrhosis in either cell subpopulation. In conclusion, the innate immune cell activity is enhanced in patients with CHC during antiviral treatment and returns to normal after its discontinuation thus possibly playing a role in their susceptibility to infections.
AB - The incidence of infections increases during treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) for chronic hepatitis C (CHC). Despite a reduction in neutrophil count, there is no clear relationship between infection occurrence and neutropenia. In the present study we investigated whether HCV treatment alters leukocyte function. We studied cell chemotaxis, reactive oxygen species, neutrophil phagocytosis, CR3 expression, and plasma colony stimulating factors (CSF) in 20 healthy subjects and 20 patients with CHC (10 with cirrhosis) at baseline, during antiviral treatment (at 4, 12, 24 weeks), and 12 weeks after discontinuation. Our results demonstrate that neutrophil chemotaxis and oxidative burst significantly increased during treatment and returned to baseline at the end of therapy. CR3 neutrophil expression was enhanced in baseline CHC compared to controls but did not change during antiviral treatment. Chemotaxis, oxidative burst, phagocytosis, and CSF levels did not differ significantly between patients before treatment and control subjects or among CHC cases according to the presence of cirrhosis in either cell subpopulation. In conclusion, the innate immune cell activity is enhanced in patients with CHC during antiviral treatment and returns to normal after its discontinuation thus possibly playing a role in their susceptibility to infections.
KW - Leukocyte function
KW - Opportunistic infection
KW - Pegylated interferon
KW - Ribavirin
UR - http://www.scopus.com/inward/record.url?scp=69949150187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69949150187&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2009.04623.x
DO - 10.1111/j.1749-6632.2009.04623.x
M3 - Conference contribution
C2 - 19758237
AN - SCOPUS:69949150187
SN - 9781573317627
VL - 1173
T3 - Annals of the New York Academy of Sciences
SP - 847
EP - 857
BT - Annals of the New York Academy of Sciences
ER -